Protagonist Therapeutics Statistics
Share Statistics
Protagonist Therapeutics has 61.98M
shares outstanding. The number of shares has increased by 4.66%
in one year.
| Shares Outstanding | 61.98M |
| Shares Change (YoY) | 4.66% |
| Shares Change (QoQ) | 3% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,487 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 6.12M, so 9.87% of the outstanding
shares have been sold short.
| Short Interest | 6.12M |
| Short % of Shares Out | 9.87% |
| Short % of Float | 11.84% |
| Short Ratio (days to cover) | 6.56 |
Valuation Ratios
The PE ratio is 8.64 and the forward
PE ratio is -44.91.
Protagonist Therapeutics's PEG ratio is
-0.02.
| PE Ratio | 8.64 |
| Forward PE | -44.91 |
| PS Ratio | 5.47 |
| Forward PS | 5.8 |
| PB Ratio | 3.52 |
| P/FCF Ratio | 13 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Protagonist Therapeutics has an Enterprise Value (EV) of 2.29B.
| EV / Sales | 5.27 |
| EV / EBITDA | 9.06 |
| EV / EBIT | 12.44 |
| EV / FCF | 12.53 |
Financial Position
The company has a current ratio of 12.48,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.48 |
| Quick Ratio | 12.48 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 40.75% and Return on Invested Capital is 35.69%.
| Return on Equity | 40.75% |
| Return on Assets | 36.95% |
| Return on Invested Capital | 35.69% |
| Revenue Per Employee | $3,503,491.94 |
| Profits Per Employee | $2,219,258.06 |
| Employee Count | 124 |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 4.22M |
| Effective Tax Rate | 1.51% |
Stock Price Statistics
The stock price has increased by 49.65% in the
last 52 weeks. The beta is 2.64, so Protagonist Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.64 |
| 52-Week Price Change | 49.65% |
| 50-Day Moving Average | 46.91 |
| 200-Day Moving Average | 42.89 |
| Relative Strength Index (RSI) | 48.03 |
| Average Volume (20 Days) | 1,248,116 |
Income Statement
In the last 12 months, Protagonist Therapeutics had revenue of 434.43M
and earned 275.19M
in profits. Earnings per share was 4.47.
| Revenue | 434.43M |
| Gross Profit | 431.47M |
| Operating Income | 252.84M |
| Net Income | 275.19M |
| EBITDA | 252.84M |
| EBIT | 252.84M |
| Earnings Per Share (EPS) | 4.47 |
Full Income StatementBalance Sheet
The company has 97.25M in cash and 10.87M in
debt, giving a net cash position of 86.38M.
| Cash & Cash Equivalents | 97.25M |
| Total Debt | 10.87M |
| Net Cash | 86.38M |
| Retained Earnings | -340.52M |
| Total Assets | 742.13M |
| Working Capital | 570.75M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 184.15M
and capital expenditures -1.35M, giving a free cash flow of 182.8M.
| Operating Cash Flow | 184.15M |
| Capital Expenditures | -1.35M |
| Free Cash Flow | 182.8M |
| FCF Per Share | 2.97 |
Full Cash Flow StatementMargins
Gross margin is 99.32%, with operating and profit margins of 58.2% and 63.34%.
| Gross Margin | 99.32% |
| Operating Margin | 58.2% |
| Pretax Margin | 64.32% |
| Profit Margin | 63.34% |
| EBITDA Margin | 58.2% |
| EBIT Margin | 58.2% |
| FCF Margin | 42.08% |
